Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second Phase 3 Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Trial Profile

Second Phase 3 Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plecanatide (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Bausch Health Companies
  • Most Recent Events

    • 09 May 2023 Results of post hoc pooled analysis (n=2176) assessing plecanatide for simultaneously improving these patient-reported outcomes, using composite endpoints, as healthcare providers must rely upon symptom improvement to measure IBS treatment success from NCT02387359 and NCT02493452 studies, presented at the Digestive Disease Week 2023.
    • 26 Oct 2022 Results of a pooled post-hoc analysis from two clinical studies (NCT02387359 and NCT02493452) assessing change from baseline at week 12 in abdominal pain and bloating symptoms in overall population and those with severe baseline abdominal pain and bloating presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
    • 26 Oct 2022 Results of post hoc pooled analysis from NCT01982240; NCT02122471, NCT02387359, NCT02493452; evaluating the potential impact of age on plecanatide efficacy in Chronic Idiopathic Constipation and IBS-C, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top